Please login to the form below

Not currently logged in
Email:
Password:

Jacques Dumas joins Nosopharm scientific advisory board

French biotech's appointments also include Dominique Breilh

Nosopharm has appointed Jacques Dumas and three others to its scientific advisory board to strengthen its preclinical development programme.

Dumas, who has over 20 years of experience of antibiotic R&D, has previously held positions as chief scientific officer at Idenix Pharmaceuticals and VP and head of strategy for AstraZeneca infectious diseases unit.

He is joined on Nosopharm's scientific advisory board by Dominique Breilh, Jean-Michel Molina and Patrice Nordmann.

Dominique Breilh runs the pharmacokinetics and clinical pharmacy laboratory at the University of Bordeaux, France; Jean-Michel Molina is professor of infectious diseases at the University of Paris Diderot; and Patrice Nordmann is professor and director of the molecular microbiology unit at Switzerland's University of Fribourg.

French biotech company Nosopharm, which focus on anti-infective research, said the four appointments reflect a new phase of development for Odilorhabdins, a novel class of antibiotics it is developing.

Philippe Villain-Guillot, CEO of Nosopharm, said: “Dominique Breilh, Jacques Dumas, Jean-Michel Molina and Patrice Nordmann have internationally renowned skills and knowledge, which is a major asset for Nosopharm.

“Their appointments reflect our desire to ramp up our development. Our aim is to run phase I clinical trials starting in 2017 to evaluate a first-generation Odilorhabdin derived from out NOSO-95 molecule.”

19th November 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...